SRPT
Sarepta Therapeutics, Inc.
SRPT
Sarepta Therapeutics, Inc.
Sarepta Therapeutics NASDAQ: SRPT outlined plans to stabilize demand for its ELEVIDYS gene therapy while advancing RNA-based programs for facioscapulohumeral muscular dystrophy, or FSHD, and myotonic
NEW YORK CITY and NEW ORLEANS, Sept. 4, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C.
Sarepta Therapeutics, Inc. (SRPT) Q2 2026 Earnings Call Transcript